An additional regulatory application is also under review in the european union, with a decision expected by the first half of 2026. See important safety & full prescribing information. Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation. Libtayo is the first medicine approved by the food and drug administration (fda) to treat cscc that has spread or cannot be cured by surgery or radiation Libtayo is not chemotherapy or radiation therapy.
OPEN
